Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
12,500 KRW
146.23 B KRW
1.49 T KRW
6.14 M
About HANMIPHARM
Sector
CEO
Jong-Yoon Lim
Headquarters
Hwaseong-si
Website
Founded
1973
ISIN
KR7128940004
FIGI
BBG000QKWSN4
Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for high blood pressure, hyperlipidemia, reflux esophagitis, and cerebrovascular disease. The company was founded by Lim Sung-Gi on June 15, 1973 and is headquartered in Hwaseong-si, South Korea.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 128940 is 278,000 KRW — it has decreased by −1.07% in the past 24 hours. Watch HANMIPHARM stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange HANMIPHARM stocks are traded under the ticker 128940.
128940 stock has fallen by −4.79% compared to the previous week, the month change is a −15.37% fall, over the last year HANMIPHARM has showed a −5.79% decrease.
We've gathered analysts' opinions on HANMIPHARM future price: according to them, 128940 price has a max estimate of 440,000.00 KRW and a min estimate of 290,000.00 KRW. Watch 128940 chart and read a more detailed HANMIPHARM stock forecast: see what analysts think of HANMIPHARM and suggest that you do with its stocks.
128940 reached its all-time high on Nov 10, 2015 with the price of 699,500 KRW, and its all-time low was 34,000 KRW and was reached on May 24, 2012. View more price dynamics on 128940 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
128940 stock is 3.45% volatile and has beta coefficient of 0.59. Track HANMIPHARM stock price on the chart and check out the list of the most volatile stocks — is HANMIPHARM there?
Today HANMIPHARM has the market capitalization of 3.53 T, it has decreased by −2.94% over the last week.
Yes, you can track HANMIPHARM financials in yearly and quarterly reports right on TradingView.
HANMIPHARM is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
HANMIPHARM revenue for the last quarter amounts to 362.10 B KRW, despite the estimated figure of 372.99 B KRW. In the next quarter, revenue is expected to reach 442.29 B KRW.
128940 net income for the last quarter is 31.00 B KRW, while the quarter before that showed 40.27 B KRW of net income which accounts for −23.03% change. Track more HANMIPHARM financial stats to get the full picture.
HANMIPHARM dividend yield was 0.14% in 2023, and payout ratio reached 4.17%. The year before the numbers were 0.16% and 7.37% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 24, 2024, the company has 2.34 K employees. See our rating of the largest employees — is HANMIPHARM on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HANMIPHARM EBITDA is 358.31 B KRW, and current EBITDA margin is 21.69%. See more stats in HANMIPHARM financial statements.
Like other stocks, 128940 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANMIPHARM stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANMIPHARM technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANMIPHARM stock shows the strong sell signal. See more of HANMIPHARM technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.